23Andme Holding Current Deferred Revenue Over Time
| ME Stock | USD 3.11 0.12 3.72% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out 23Andme Holding Performance and 23Andme Holding Correlation. 23Andme |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 23Andme Holding. If investors know 23Andme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 23Andme Holding listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (122.52) | Revenue Per Share 8.224 | Quarterly Revenue Growth (0.34) | Return On Assets (0.26) | Return On Equity (1.54) |
The market value of 23Andme Holding is measured differently than its book value, which is the value of 23Andme that is recorded on the company's balance sheet. Investors also form their own opinion of 23Andme Holding's value that differs from its market value or its book value, called intrinsic value, which is 23Andme Holding's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 23Andme Holding's market value can be influenced by many factors that don't directly affect 23Andme Holding's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 23Andme Holding's value and its price as these two are different measures arrived at by different means. Investors typically determine if 23Andme Holding is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 23Andme Holding's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare 23Andme Holding and related stocks such as IDEXX Laboratories, Twist Bioscience Corp, and Guardant Health Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDXX | 13.2 M | 15 M | 20.2 M | 21.5 M | 31.8 M | 25.6 M | 27.4 M | 29.2 M | 41.3 M | 41.5 M | 42.6 M | 40 M | 37.9 M | 37.2 M | 25 M |
| TWST | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 7.6 M | 7.6 M | 16.4 M | 18.8 M | 28.8 M | 3.5 M | 3.5 M | 2.1 M | 2 M |
| GH | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 3.1 M | 16.1 M | 12.3 M | 8.6 M | 11.3 M | 17.4 M | 18 M | 12.2 M |
| A | 241 M | 420 M | 439 M | 435 M | 258 M | 269 M | 291 M | 324 M | 336 M | 386 M | 441 M | 461 M | 505 M | 580.8 M | 364.3 M |
| TMO | (200 K) | 192.5 M | 196.5 M | 198.9 M | 311.9 M | 317.9 M | 485.9 M | 719 M | 809 M | 916 M | 1.3 B | 2.7 B | 2.6 B | 2.7 B | 2.8 B |
| DHR | 1.3 B | 730 M | 730 M | 686.5 M | 766.5 M | 633.7 M | 539.8 M | 666 M | 685.2 M | 687.8 M | 1.2 B | 1.6 B | 1.6 B | 1.5 B | 987.2 M |
| GENE | 662.1 K | 266.6 K | 320.8 K | 153.2 K | 77.3 K | 635 | 635 | 635 | 635 | 635 | 635 | 814.1 K | 849.2 K | 741.6 K | 378.3 K |
| ILMN | 10 M | 63.6 M | 69.6 M | 64.4 M | 95.6 M | 117.6 M | 141.1 M | 150 M | 175 M | 167 M | 186 M | 234 M | 245 M | 252 M | 264.6 M |
| WAT | 46 M | 109.9 M | 121.5 M | 128.1 M | 129.7 M | 141.5 M | 148.8 M | 166.8 M | 165 M | 176.4 M | 198.2 M | 227.6 M | 227.9 M | 256.7 M | 140.6 M |
23Andme Holding and related stocks such as IDEXX Laboratories, Twist Bioscience Corp, and Guardant Health Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
Check out 23Andme Holding Performance and 23Andme Holding Correlation. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
23Andme Holding technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.